Panoral (Cefaclor Monohydrate)

Cefaclor, the active ingredient in Panoral, is a second‑generation cephalosporin presented as an oral tablet for systemic use. It treats a range of bacterial infections in adults and children, including sinusitis, otitis media, pneumonia, urinary tract and skin infections.

GNH USA supplies Panoral as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation for export to EU and other markets. Customers benefit from reliable supply chains and responsive technical support.

Cefaclor is indicated for several bacterial infections affecting the respiratory, urinary and skin systems.

Acute bacterial sinusitis: eradicates sinus pathogens, relieving congestion and preventing complications. Acute otitis media: targets common ear pathogens, reducing pain and inflammation. Community‑acquired pneumonia: covers typical respiratory bacteria, supporting clinical recovery. Uncomplicated urinary tract infections: eliminates uropathogens, relieving dysuria and preventing recurrence. Skin and soft‑tissue infections: treats cellulitis and wound infections caused by susceptible organisms, promoting healing.

Cefaclor may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea: mild gastrointestinal upset. - Diarrhea: loose stools, sometimes watery. - Vomiting: occasional emesis. - Abdominal pain: crampy discomfort. - Rash: mild skin erythema or pruritus. - Headache: transient tension‑type headache.

Serious or Rare Side Effects: - Severe allergic reaction (anaphylaxis): respiratory distress, hypotension, urticaria. - Clostridioides difficile‑associated colitis: severe diarrhea with abdominal pain. - Stevens‑Johnson syndrome/toxic epidermal necrolysis: extensive skin detachment and mucosal involvement. - Hemolytic anemia: sudden drop in hemoglobin with fatigue. - Liver enzyme elevation: hepatitis signs, jaundice. - Neutropenia: low white blood cell count, increased infection risk.

Before prescribing cefaclor, clinicians should consider several safety and handling factors.

- Assess allergy history: avoid in patients with known cephalosporin or penicillin hypersensitivity. - Evaluate renal function: dose adjustment may be required in impaired clearance. - Monitor for superinfection: prolonged use can lead to fungal or bacterial overgrowth. - Caution in pregnancy: limited data; use only if benefit outweighs risk. - Use with caution in breastfeeding: small amounts excreted in milk, assess infant risk. - Store below 25°C: keep in the original pack, protect from moisture.

Cefaclor can interact with other medicines, altering efficacy or safety.

Major Interactions (Avoid): - Probenecid: reduces renal excretion, increasing cefaclor plasma levels and toxicity risk. - Oral anticoagulants (warfarin): may enhance anticoagulant effect, increasing bleeding risk.

Moderate Interactions (Monitor Closely): - Metformin: reduced renal clearance may increase metformin levels; monitor for lactic acidosis. - Oral contraceptives: possible reduction in efficacy; advise additional contraceptive measures. - Diuretics (loop, thiazide): may affect renal function, requiring monitoring of cefaclor clearance. - Antacids containing aluminum or magnesium: may impair cefaclor absorption; separate dosing by at least 2 hours.